Want to join the conversation?
$ABBV said that its adjusted R&D expense was 15.9% of net revenues in 4Q15, reflecting funding actions in support of its mid- and late-stage pipeline. The company's adjusted operating margin in during quarter was 40.1%, compared to 35.8% in 4Q14. On a GAAP basis, the operating margin was 33%.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)